The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Robyn Karnauskas - Truist Securities - Analyst
: Great, thanks for taking my question and congrats on the first earnings call to you. So, number one, for tapinarof, you noted that a lot of patients
-- and maybe you could restate the percent of patients, when they go on their biologic they also maintain them on the topical. When you're thinking
about pricing, I know you said you haven't decided yet, how much does that factor into that decision? And what's your latest thoughts on pricing
given insights pricing strategy?
And the second question is on the IT lawsuit with Moderna. Could you give an update on the case? Maybe give us a sense, just legally, what kind
of news flow we'll hear over the next six months. Thanks.
Question: Robyn Karnauskas - Truist Securities - Analyst
: Have you [happened to do] a combo study? For combo use when you go on your biologic do you have to do any study? I know with steroids it
seems like that seems easy to do. Just, do you have to do additional work to get that use once you launch (inaudible)?
Question: Douglas Tsao - H.C. Wainwright - Analyst
: Just first maybe on tapinarof, I'm just curious, how do you see the product? Or do you see the product being used differently in psoriasis versus
tapinarof? Meaning do you see it being used in combination with biologics more in one versus the other or frontline therapy in one versus the
other? And does that affect or sort of influence how you think about pricing? Thank you.
Question: Douglas Tsao - H.C. Wainwright - Analyst
: Okay great, that's really helpful. And then just -- and Matt, just as one follow-up just as you think about the pipeline and the development of the
business, how do you feel about sort of scaling? And just given how broad your pipeline already is, and between the discovery engine as well as
further business development, at what point do you think you need to maybe pump the brakes a little just to make sure that as a business you
don't get ahead of yourselves. Thank you.
Question: Geoffrey Porges - SVB Leerink - Analyst
: Congratulations from us also on the IPO and the new quarterly call. Three questions if I may. First, on tapinarof, the FDA certainly surprised us
recently with the quotient they've shown with respect to labeling even for topical agents, most obviously with Opzelura. Should we expect there
to be any form of warning language in the tapinarof label associated with exposure or even very high levels of exposure to the active?
And then secondly, a couple of financial questions. Do you have any intention to change the current ownership structure with respect to Immunovant
or Aruvant? And then lastly, Richard, is your $175 million or so expense rate for Q3 the right basis for Q4 and for us to be modeling for next year
on a quarterly basis? Or are there some trends that we should be aware of? Thank you.
Question: Dennis Ding - Jefferies LLC - Analyst
: I guess I have two questions. Number one, can you please help frame for investors how to think about or even value some of your past BDs in
non-therapeutics, particularly like Silicon Therapeutics, Lokavant? Can you just provide some clarity on how does exposure in these areas contribute
to Roivant's overall story, particularly over the long term?
And then as a follow-up, can you just comment on the internal bar or criteria that you guys use when considering building out additional Vants?
And are there any interesting areas or technologies that you guys are seeing right now? Thank you very much.
|
